High-CSD melanomas have a threefold higher tumor mutation burden than low-CSD melanomas [21], and a higher mutation burden is associated with enhanced sensitivity to ICIs, including anti-PD-1 [22]. This evidence concerns the gene PDCD1 and melanoma.